Enimmune Corporation (TPEX:6564)
Taiwan · Delayed Price · Currency is TWD 19.95
+0.15 (0.76%)
At close: Feb 11, 2026
Enimmune Market Cap
Enimmune has a market cap or net worth of 1.44 billion as of February 11, 2026. Its market cap has decreased by -25.97% in one year.
Market Cap
1.44B
Enterprise Value
1.34B
Revenue
42.23M
Ranking
n/a
PE Ratio
n/a
Stock Price
19.95
Market Cap Chart
Since September 18, 2018, Enimmune's market cap has increased from 1.33B to 1.44B, an increase of 8.33%. That is a compound annual growth rate of 1.09%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 1.43B | -3.88% |
| Dec 31, 2025 | 1.49B | -17.27% |
| Dec 31, 2024 | 1.80B | -27.21% |
| Dec 29, 2023 | 2.47B | -38.63% |
| Dec 30, 2022 | 4.02B | 69.85% |
| Dec 30, 2021 | 2.37B | -11.74% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
| Sep 18, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Advagene Biopharma | 1.90B |
| Genomics BioSci & Tech. | 1.80B |
| NeoCore Technology | 1.54B |
| Abnova (Taiwan) | 1.53B |
| GenMont Biotech Incorporation | 1.52B |
| Great Novel Therapeutics Biotech & Medicals | 1.46B |
| Meribank Biotech | 1.30B |
| GeneReach Biotechnology | 1.20B |